Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Acquires Liquid Chromatography Firm PepSep, Enters OEM Agreement with IonOpticks

NEW YORK – Bruker said Friday that it has acquired Danish liquid chromatography company PepSep and entered into an OEM agreement with IonOpticks of Australia for nanoLC columns.

Bruker uses nanoLC columns from Marslev-based PepSep in its nanoElute UHPLC system and said the company's columns, specialty emitters, and components will allow it to optimize its nanoflow proteomics workflows.

Under the OEM agreement with IonOpticks, the Melbourne-based firm will produce Bruker's Focus series nanoLC columns with performance identical to IonOpticks' Aurora columns, which feature integrated packed emitter tips and provide high-quality peak shapes and high separation power.

"The addition of PepSep’s column portfolio combined with the IonOpticks high-performance pulled tip columns provide our timsTOF customers more nanoLC choices to advance their applications," Michael Krawitzky, Bruker's product manager for LC-MS consumables, said in a statement. "Our timsTOF customers expect excellent sensitivity and robustness, which this combined Bruker and OEM nanoLC portfolio will add."

"It is great to be part of Bruker as it allows the PepSep team to focus on innovation in separations for ultra-high throughput proteomics on the timsTOF platform," said PepSep founder Peter Nielsen. "Matching separations technology that is ultra-robust and delivers the best sensitivity for high-speed TIMS/PASEF detection, with the ease of use of non-integrated tips, was important, and we now can continue to develop chemistries to drive performance enhancements for 4D-Proteomics and 4D-Lipidomics applications."

Financial and other terms of the agreements were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.